Table 1.
: Baseline characteristics of CAM cases.
| Characteristics | Total | Positive | Negative | p-value |
|---|---|---|---|---|
| Age (mean ± SD) (n = 208) | 52.84 ± 14.07 | 52.82 ± 11.61 | 52.88 ± 12.83 | 0.973 |
| Sex (n = 208) Male Female |
136 (65.4 %) 72 (34.6 %) |
81 (63.8 %) 46 (36.2 %) |
55 (67.9 %) 26 (32.1 %) |
0.542 |
| Rural/Urban (n = 194) Rural Urban |
99 (51.0 %) 95 (49.0 %) |
67 (56.3 %) 52 (43.7 %) |
32 (42.7 %) 43 (57.3 %) |
0.064 |
| Vaccinated (n = 194) No Yes |
160 (82.5 %) 34 (17.5 %) |
95 (79.8 %) 24 (20.2 %) |
65 (86.7 %) 10 (13.3 %) |
0.223 |
| Vaccine doses given (n = 34) One Two |
30 (15.4 %) 04 (2.1) |
19 (16.0 %) 4 (3.4 %) |
11 (13.3 %) 0 (0) |
0.28 |
| Blood Group (n = 181) A B O AB |
55 (30.4 %) 35 (19.3 %) 69 (38.1 %) 22 (12.2 %) |
35 (31.3 %) 20 (17.9 %) 44 (39.3 %) 13 (11.6 %) |
20 (29.0 %) 15 (21.7 %) 25 (36.2 %) 9 (13.0 %) |
0.901 |
| BMI kg/m2(mean ± SD),(n = 181) | 24.57 ± 1.82 | 24.59 ± 1.81 | 24.55 ± 1.85 | 0.892 |
| Diabetes (n = 208) | 200 (96.2 %) | 124 (97.6 %) | 76 (93.8 %) | 0.163 |
| Duration of diabetes (months) (n = 113) | 6.90 ± 4.95 | 7.06 ± 5.32 | 6.69 ± 4.46 | 0.698 |
| Hypertension (n = 207) | 61 (29.5) | 38 (30.2 %) | 23 (28.4 %) | 0.786 |
| Chronic kidney disease (n = 206) | 8 (3.9) | 4 (3.2 %)% | 4 (3.2 %) | 0.509 |
| Admission during COVID (n = 200) Yes No |
90 (45.0 %) 110 (55.0 %) |
56 (46.3 %) 65 (53.7 %) |
34 (43.0 %) 45 (57.0 %) |
0.652 |
| Drugs taken during COVID-19 infection | ||||
| Steroid intake(n = 202) | 131 (64.9 %) | 81 (65.9 %) | 50 (63.3 %) | 0.710 |
| Ivermectin intake (n = 199) | 152 (76.4 %) | 96 (78.7 %) | 56 (72.7 %) | 0.335 |
| Antibiotics intake (n = 200) | 173 (86.5 %) | 108 (87.8 %) | 65 (84.4 %) | 0.495 |
| Zinc intake (n = 201) | 170 (84.6 %) | 107 (87.0 %) | 63 (80.8 %) | 0.234 |
| Ayurveda medications (n = 190) | 109 (57.4 %) | 69 (54.3 %) | 40 (63.5 %) | 0.229 |
| Inhalational O2 given (n = 200) | 79 (39.5 %) | 47 (38.5 %) | 32 (41.0 %) | 0.724 |
| Steam inhalation (n = 180) | 123 (68.3 %) | 70 (64.8 %) | 53 (73.6 %) | 0.214 |
| Gargling (n = 179) | 104 (58.1 %) | 58 (54.2 %) | 46 (63.9 %) | 0.198 |
| Baseline investigations | ||||
| Total WBC Count (n = 204) | 11,550.17 ± 11,817.55 | 10,638.96 ± 5573.34 | 12,991.97 ± 17,625.07 | 0.167 |
| Neutrophil (n = 204) % | 73.48 ± 11.046 | 73.20 ± 10.976 | 73.92 ± 11.212 | 0.649 |
| Lymphocyte (n = 204) % | 17.175 ± 10.0045 | 17.509 ± 10.3753 | 16.646 ± 9.4286 | 0.550 |
| CD4 count (n = 167) | 538.43 ± 233.404 | 536.33 ± 238.349 | 541.72 ± 227.220 | 0.885 |
| Fasting blood sugar (n = 206) | 184.20 ± 87.597 | 191.39 ± 95.230 | 172.88 ± 73.143 | 0.140 |
| Total Protein (n = 204) | 6.655 ± 0.8863 | 6.683 ± 0.8723 | 6.610 ± 0.9117 | 0.567 |
| Albumin (n = 204) | 3.099 ± 0.5044 | 3.094 ± 0.5259 | 3.108 ± 0.4714 | 0.847 |
| Serum glutamic-oxaloacetic transaminase (n = 204) | 40.267 ± 32.1565 | 40.259 ± 34.3758 | 40.278 ± 28.5055 | 0.997 |
| Serum glutamic-pyruvic transaminase (n = 204) | 45.065 ± 32.3662 | 44.850 ± 32.1088 | 45.405 ± 32.9726 | 0.905 |
| Serum Creatinine(n = 204) | 1.109 ± 0.9021 | 1.116 ± 0.9359 | 1.099 ± 0.8518 | 0.894 |
| Serum Ferritin (n = 166) | 126.7550 ± 161.85323 | 147.5863 ± 172.86456 | 97.4704 ± 141.02900 | 0.049 |
| HbA1c (n = 201) | 10.1626 ± 2.56382 | 10.4528 ± 2.55264 | 9.7049 ± 2.53030 | 0.044 |